Boards
Medical research charity Boards need to adapt to the new world or risk failure – Volume 2
In volume 1 of this blog, I looked at the tension caused by the growing demands on medical research charities and their heightened financial...
Medical research charity Boards need to adapt to the new world or risk failure – Volume 1
As we come out of the first wave of the Covid-19 pandemic, the issues affecting the Boards of medical research charities are, in many...
Never has the life sciences sector been more important – it’s time for Boards to raise their game
In recent conversations with investors, availability of the right people to join biotech Boards has come up as a recurring theme and the prevailing...
Who guards the Guards in life science companies?
This isn’t a new question; it’s been asked by every civilisation, from the Greeks on holding people in power to account, and the Romans...
Diversity: A call to arms for Biotech Leaders and Investors
A panel discussion, led by The RSA Group, at the recent BIA UK CEO & Investor Forum discussed the demographic time bomb facing biotech boards...
Building talent and saving lives
London was the setting last week for the 25th Annual Meeting of the International Society for Cellular Therapy. The huge increase of clinical trials...
What next for EU and UK biotech boards?
In light of the UK’s decision to leave the EU, it’s worth revisiting our recent Talent Equity® report on what makes successful biotech boards. The question...
New study looks at the impact of boards on biotech company performance
UK companies performing less well than those in mainland Europe RSA has published the latest of its Talent Equity® reports, an analysis of biotech company...